Skip to main content

Table 3 Use of anticoagulant agents, antiplatelet agents, and mechanical prophylaxis

From: Incidence of venous thromboembolism and bleeding events in patients with lower extremity orthopedic surgery: a retrospective analysis of a Japanese healthcare database

 

TKAa

THAa

HFSa

Rupture of Achilles tendona

Simple fracture of lower extremitiesa

 

n = 5023

n = 3856

n = 20,991

n = 572

n = 6639

Anticoagulant agents

     

 Warfarin

436 (8.7)

219 (5.7)

1462 (7.0)

6 (1.0)

156 (2.3)

 Unfractionated heparin

1369 (27.3)

1358 (35.2)

3574 (17.0)

3 (0.5)

397 (6.0)

 Low molecular weight heparin

803 (16.0)

958 (24.8)

1003 (4.8)

0 (0.0)

47 (0.7)

 Factor Xa inhibitor

3000 (59.7)

1937 (50.2)

3224 (15.4)

3 (0.5)

157 (2.4)

  NOAC s

1443 (28.7)

816 (21.2)

1954 (9.3)

1 (0.2)

64 (1.0)

  Fondaparinux

1570 (31.3)

1126 (29.2)

1280 (6.1)

2 (0.3)

93 (1.4)

 Others

3 (0.1)

2 (0.1)

45 (0.2)

0 (0.0)

4 (0.1)

Antiplatelet agents

870 (17.6)

470 (12.2)

4645 (22.1)

17 (3.0)

513 (7.7)

Mechanical prophylaxis

4663 (92.8)

3583 (92.9)

18,191 (86.7)

308 (53.8)

4875 (73.4)

  1. Other abbreviations are the same as Table 1
  2. NOAC s novel oral anticoagulants (Edoxaban, Dabigatran, Rivaroxaban and Apixaban)
  3. aNo. (%)